NDSI
PBE icon

Newman Dignan & Sheerar Inc’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Newman Dignan & Sheerar Inc’s Portfolio PBE Stock Details PBE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$840K Sell
9,370
-200
-2% -$16.5K 0.16% 100
2026
Q1 		$758K Sell
9,570
-500
-5% -$40.4K 0.16% 98
2025
Q4 		$827K Buy
10,070
+298
+3% +$23.1K 0.17% 99
2025
Q3 		$683K Sell
9,772
-700
-7% -$47.3K 0.15% 106
2025
Q2 		$671K Sell
10,472
-400
-4% -$24.8K 0.15% 102
2025
Q1 		$690K Hold
10,872
– – 0.19% 93
2024
Q4 		$723K Sell
10,872
-550
-5% -$37.9K 0.19% 95
2024
Q3 		$781K Buy
11,422
+500
+5% +$34.6K 0.19% 95
2024
Q2 		$708K Sell
10,922
-360
-3% -$22.8K 0.18% 102
2024
Q1 		$730K Sell
11,282
-1,404
-11% -$91.4K 0.2% 99
2023
Q4 		$835K Buy
12,686
+1,500
+13% +$87.2K 0.25% 92
2023
Q3 		$638K Sell
11,186
-1,625
-13% -$99.1K 0.21% 99
2023
Q2 		$785K Sell
12,811
-440
-3% -$27.5K 0.24% 95
2023
Q1 		$832K Buy
13,251
+50
+0.4% +$3.22K 0.27% 87
2022
Q4 		$838K Hold
13,201
– – 0.28% 86
2022
Q3 		$778 Hold
13,201
– – 0.12% 85
2022
Q2 		$762K Hold
13,201
– – 0.26% 90
2022
Q1 		$819 Sell
13,201
-200
-1% -$12.2K 0.16% 88
2021
Q4 		$954K Buy
13,401
+200
+2% +$14.5K 0.29% 86
2021
Q3 		$988K Hold
13,201
– – 0.29% 75
2021
Q2 		$1.02M Hold
13,201
– – 0.34% 71
2021
Q1 		$974K Buy
13,201
+460
+4% +$34.8K 0.35% 72
2020
Q4 		$894 Sell
12,741
-1,200
-9% -$76K 0.14% 71
2020
Q3 		$789K Buy
+13,941
New +$819K 0.33% 73
2019
Q3 		– Sell
-15,365
Closed -$822 – 156
2019
Q2 		$822 Buy
+15,365
New +$797K 0.02% 71
2018
Q3 		– Sell
-14,115
Closed -$772 – 158
2018
Q2 		$772 Hold
14,115
– – 0.05% 63
2018
Q1 		$689K Sell
14,115
-476
-3% -$24.3K 0.35% 73
2017
Q4 		$688K Hold
14,591
– – 0.34% 76
2017
Q3 		$729K Buy
14,591
+54
+0.4% +$2.56K 0.39% 69
2017
Q2 		$664K Hold
14,537
– – 0.37% 78
2017
Q1 		$615 Sell
14,537
-260
-2% -$10.9K 0.27% 82
2016
Q4 		$574K Buy
+14,797
New +$597K 0.35% 80
2016
Q3 		– Sell
-16,897
Closed -$625K – 149
2016
Q2 		$625K Buy
+16,897
New +$663K 0.39% 73
2016
Q1 		– Sell
-22,022
Closed -$1.11M – 137
2015
Q4 		$1.11M Sell
22,022
-103
-0.5% -$5.09K 0.79% 38
2015
Q3 		$1.01M Sell
22,125
-2,500
-10% -$140K 0.65% 34
2015
Q2 		$1.44M Sell
24,625
-1,600
-6% -$91.5K 1.03% 28
2015
Q1 		$1.45M Sell
26,225
-1,625
-6% -$87.8K 1.03% 28
2014
Q4 		$1.4K Sell
27,850
-475
-2% -$23.2K 0.84% 30
2014
Q3 		$1.31M Buy
+28,325
New +$1.28M 0.98% 29
2014
Q2 		– Sell
-31,525
Closed -$1.31M – 147
2014
Q1 		$1.31M Sell
31,525
-3,150
-9% -$135K 0.93% 32
2013
Q4 		$1.28K Sell
34,675
-1,275
-4% -$45.7K 0.06% 31
2013
Q3 		$1.26M Sell
35,950
-50
-0.1% -$1.66K 0.98% 29
2013
Q2 		$1.04K Buy
+36,000
New +$1.02M 0.08% 37

Other funds holding PBE

YIA
YHB Investment Advisors West Hartford, Connecticut $1.56B AUM 27.39% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
RA
RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return
ACS
Archford Capital Strategies Swansea, Illinois $987M AUM 29.31% 1-Year Est. Return
DAS
Dynamic Advisor Solutions Phoenix, Arizona $3.53B AUM 22.61% 1-Year Est. Return
PA
PFG Advisors Phoenix, Arizona $1.98B AUM 28.18% 1-Year Est. Return
FPB
First PREMIER Bank Sioux Falls, South Dakota $619M AUM 20.21% 1-Year Est. Return
HIA
Harbor Investment Advisory Lutherville, Maryland $1.43B AUM 30.71% 1-Year Est. Return

Newman Dignan & Sheerar Inc's PBE Position: Q2 2026 in Review

Newman Dignan & Sheerar Inc reduced its Invesco Biotechnology & Genome ETF (PBE) stake by 2.1% in Q2 2026, selling an estimated $16.5K and leaving 9,370 shares worth $840K. The position accounts for 0.16% of the portfolio, ranked #100.

Newman Dignan & Sheerar Inc first reported a position in PBE in Q2 2013 and has held it in 43 quarters since. The position peaked at $1.45M in Q1 2015. 9 funds tracked by Wall St. Rank hold PBE as of Q2 2026.

  • Newman Dignan & Sheerar Inc held 9,370 shares of Invesco Biotechnology & Genome ETF worth $840K as of Q2 2026.
  • Newman Dignan & Sheerar Inc sold 200 Invesco Biotechnology & Genome ETF shares in Q2 2026, an estimated $16.5K.
  • Invesco Biotechnology & Genome ETF made up 0.16% of Newman Dignan & Sheerar Inc's portfolio in Q2 2026, its #100 holding.
  • Newman Dignan & Sheerar Inc first reported a position in Invesco Biotechnology & Genome ETF in Q2 2013 and has held it in 43 quarters since.
  • Newman Dignan & Sheerar Inc's Invesco Biotechnology & Genome ETF position peaked at $1.45M in Q1 2015.
  • 9 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q2 2026.

Based on Newman Dignan & Sheerar Inc's 13F filing for Q2 2026, filed 14 Jul 2026.